Mylan N.V. (MYL) has been under a strong bear grip, hence the stock is down -3.25% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.54% in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.04% in the last 1 week, and is up 0.98% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 2.78% and the 50-Day Moving Average is 4.9%.
Mylan N.V. (NASDAQ:MYL): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $45.83 and $45.15 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $45.90. The buying momentum continued till the end and the stock did not give up its gains. It closed at $45.45, notching a gain of 0.15% for the day. The total traded volume was 2,696,040 . The stock had closed at $45.38 on the previous day.
The company Insiders own 0.71% of Mylan N.V. shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by 17.32% . Institutional Investors own 66.51% of Mylan N.V. shares. During last six month period, the net percent change held by insiders has seen a change of -11.04%. In a related news, The Securities and Exchange Commission has divulged in a Form 4 filing that the director of Mylan N.V., Maroon Joseph C Md had purchased shares worth of $75,067 in a transaction dated on June 3, 2016. A total of 1,670 shares were purchased at a price of $44.95 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Mylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Companys generic pharmaceutical business is conducted primarily in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Companys API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.